Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Active Biotech AB ( (SE:ACTI) ) has shared an update.
Active Biotech AB has announced a rights issue of shares amounting to approximately SEK 70 million, approved by the extraordinary general meeting. The company has published an information document regarding this rights issue, which has been registered with the Swedish Financial Supervisory Authority. This move is expected to support the company’s ongoing clinical development projects and strengthen its financial position, potentially impacting its market presence in the biotechnology sector.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company has a portfolio of projects including tasquinimod and laquinimod, which are small molecule immunomodulators, and naptumomab, a targeted anti-cancer immunotherapy. Their core focus is on developing tasquinimod for myelofibrosis, a rare blood cancer.
Average Trading Volume: 5,355,132
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK100.4M
See more data about ACTI stock on TipRanks’ Stock Analysis page.